Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Preoperative Chemotherapy For Women With Operable Breast Cancer.
J. Mieog, J. A. van der Hage, C. V. D. van de Velde
Published 2007 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
BACKGROUND Currently, preoperative chemotherapy is the standard of care in locally advanced breast cancer to achieve local tumour downsizing in order to make surgery possible. Since the early 1980s, the role of preoperative chemotherapy in early stage (or operable) breast cancer has been the subject of study. Potential advantages are early introduction of systemic therapy, determination of chemosensitivity, reduction of tumour volume and downstaging of surgical requirement. Concerns exist about local control after downsized surgery and the delay of local treatment in patients with tumours resistant to chemotherapy. OBJECTIVES To assess the effectiveness of preoperative chemotherapy in women with operable breast cancer when compared to postoperative chemotherapy. SEARCH STRATEGY The Specialised Register maintained by the Editorial Base of the Cochrane Breast Cancer Group was searched on 4th of August 2005. SELECTION CRITERIA Randomised trials comparing preoperative chemotherapy with postoperative in women with operable breast cancer. DATA COLLECTION AND ANALYSIS Studies were assessed for eligibility and quality, and data were extracted by two independent review authors. Hazard ratios were derived for time-to-event outcomes directly or indirectly using the methods described by Parmar. Relative risks were derived for dichotomous outcomes. Meta-analyses were performed using fixed effect model. MAIN RESULTS We identified 14 eligible studies which randomised a total of 5,500 women. Median follow-up ranged from 18 to 124 months. Eight studies described a satisfactory method of randomisation.Data, based on 1139 estimated deaths in 4620 women available for analysis, show equivalent overall survival rates with a HR of 0.98 (95% CI, 0.87 to 1.09; p, 0.67; no heterogeneity). Preoperative chemotherapy increases breast conservation rates, yet at the associated cost of increased loco regional recurrence rates. However, this rate was not increased as long as surgery remains part of the treatment even after complete tumour regression (HR, 1.12; 95% CI, 0.92 to 1.37; p, 0.25; no heterogeneity. Preoperative chemotherapy was associated with fewer adverse effects. Pathological complete response is associated with better survival than residual disease (HR, 0.48; 95% CI, 0.33 to 0.69; p, < 10-4). AUTHORS' CONCLUSIONS This review suggests safe application of preoperative chemotherapy in the treatment of women with early stage breast cancer in order to down-stage surgical requirement, to evaluate chemosensitivity and to facilitate translational research.
This paper references
Neoadjuvant chemotherapy in operable breast cancer.
S. Scholl (1991)
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
H. Bear (2006)
Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation.
S. Vinnicombe (1996)
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
Y. Wang (2005)
Multimodal treatment of locoregionally advanced breast cancer
G. Hortobagyi (1983)
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer
J. Chang (2003)
Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer.
J. Hannemann (2005)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials
M. Clarke (2005)
Risk factors for local recurrence after breast‐conserving surgery
I. Fredriksson (2003)
Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up.
G. Bonadonna (1995)
Neo-adjuvant chemotherapy for operable breast cancer induces apoptosis
Z. Shao (2004)
Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study.
T. Evans (2005)
Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18.
N. Wolmark (2001)
Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation.
B. Fisher (2002)
New Guidelines to Evaluate the Response to Treatment in Solid Tumors.
P. Therasse (2000)
A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors.
B. Fisher (1989)
Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS).
L. Mauriac (1999)
Assessment of response to therapy in advanced breast cancer. A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland
J. L. Hayward (1978)
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.
M. Ayers (2004)
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
A. Buzdar (2005)
Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta‐Analysis
J. Deeks (2008)
Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more.
G. Bonadonna (1990)
Health-related quality-of-life measurement in randomized clinical trials in breast cancer--taking stock.
P. Goodwin (2003)
Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre.
L. Mauriac (1991)
International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations.
M. Kaufmann (2003)
Local recurrence after breast-conserving therapy for invasive breast cancer: high incidence in young patients and association with poor survival.
P. H. Elkhuizen (1998)
P73 Neoadjuvant therapy in stage II with T≥4CM and stage III breast cancer
K. Enomoto (1998)
Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival.
S. Cleator (2005)
Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy
G. Hortobágyi (1988)
Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2).
S. Chua (2005)
Late local recurrences in a randomised trial comparing conservative treatment with total mastectomy in early breast cancer patients.
R. Arriagada (2003)
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
B. Fisher (1998)
Advanced primary breast cancer: assessment at mammography of response to induction chemotherapy.
M. C. Segel (1988)
The impact of breast-conserving treatment and mastectomy on the quality of life of early-stage breast cancer patients: a review.
G. Kiebert (1991)
Chemotherapy before and after mastectomy in stage III breast cancer.
M. Perloff (1982)
Eighteen‐year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy
M. Poggi (2003)
Preoperative FLAC/Granulocyte-Colony-Stimulating Factor Chemotherapy for Stage II Breast Cancer: A Prospective Randomized Trial
D. Danforth (2003)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
O. Abe (2005)
Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis.
T. Whelan (2000)
Bias in meta-analysis detected by a simple, graphical test
M. Egger (1997)
Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer.
V. Semiglazov (1994)
Neoadjuvant chemotherapy in the conservative management of breast cancers: study of 143 patients.
C. Jacquillat (1986)
Locally Advanced Breast Cancer.
V. Valero (1996)
European Cooperative Trial in Operable Breast Cancer (ECTO): Improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF)
L. Gianni (2005)
Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6.
S. Scholl (1994)
Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer Cooperative Group and the Danish Breast Cancer Cooperative Group.
G. Van tienhoven (1999)
Beta blockade during and after myocardial infarction: an overview of the randomized trials.
S. Yusuf (1985)
Breast tumour response to primary chemotherapy predicts local and distant control as well as survival.
S. Scholl (1995)
Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.
J. A. van der Hage (2001)
Primary systemic therapy in operable breast cancer.
A. Wolff (2000)
Carcinoma of the breast.
C. Haagensen (1948)
Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Danish Breast Cancer Cooperative Group.
M. Blichert-Toft (1992)
Impact of locoregional treatment on the early-stage breast cancer patients: a retrospective analysis.
J. A. van der Hage (2003)
Predictors of patients’ choices for breast-conserving therapy or mastectomy: a prospective study
S. Molenaar (2004)
Long-Term Results of a Randomized Trial Comparing Breast-Conserving Therapy With Mastectomy: European Organization for Research and Treatment of Cancer 10801 Trial
J. A. V. Dongen (2000)
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
I. Smith (2005)
Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis--an intergroup study.
E. Mansour (1998)
Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging
D. C. Abraham (1996)
Prospective randomized study of surgical morbidity following primary systemic therapy for breast cancer
P. Forouhi (1995)
Local recurrence in the breast after conservative surgery--a study of prognosis and prognostic factors in 391 women.
I. Fredriksson (2002)
Textbook of Breast Cancer: A Clinical Guide to Therapy
G. Bonadonna (1997)
Randomized trial comparing neo‐adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0‐2 M0)
S. Deo (2003)
Long-term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer.
A. Voogd (2005)
Quantifying heterogeneity in a meta-analysis.
J. Higgins (2002)
Meta‐analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer
Y. Xing (2006)
Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy.
J. Gazet (2001)
Conservation surgery after primary chemotherapy in large carcinomas of the breast.
U. Veronesi (1993)
A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer.
A. Makris (1998)
Effects of preoperative chemotherapy on the morphology of resectable breast carcinoma.
F. Sharkey (1996)
Systematic reviews in health care : meta-analysis in context
M. Egger (2001)
Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.
M. K. Parmar (1998)
Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer.
U. Veronesi (2002)
P78 Primary chemotherapy in conservative treatment of stage II breast cancer patients
V. Ostapenko (1998)
Short and long‐term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial
P. Broët (2004)
Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer.
B. Fisher (1995)
Neoadjuvant chemotherapy in operabla breast cancer
S. Scholl (1991)
Preoperative chemotherapy followed by mastectomy for locally advanced breast cancer
P. Schick (1983)
The Role of Magnetic Resonance Imaging in Diagnosis and Management of Breast Cancer
D. Pavic (2004)
This paper is referenced by
Breast Cancer Biomarker Changes after Neoadjuvant Chemotherapy : A Single Institution Experience and Literature
S. Apple (2017)
Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy
Z. Al‐Hilli (2019)
Evaluación de la respuesta patológica a la quimioterapia neoadyuvante en mama y axila según los fenotipos moleculares del cáncer de mama
A. R. Guindo (2016)
Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada
C. Attard (2015)
Novel evaluation scale for QOL (QOL-ACD-BP) in preoperative chemotherapy for breast cancer
K. Takada (2018)
Quality of surgical treatment in breast cancer
K. Ojala (2018)
Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience.
M. Vetter (2017)
Neoadjuvant chemotherapy in non‐metastatic breast cancer: a study on practice trends in a regional cancer treatment service
E. Ang (2019)
Breast cancer tailored staging using molecular imaging
S. C. Teixeira (2017)
Tumor-Infiltrating Lymphocytes and Breast Cancer: Are Immune Checkpoint Inhibitors Ready for Prime Time in Breast Cancer?
A. Cvetanović (2016)
Comparison of robustness against missing values of alternative decision tree and multiple logistic regression for predicting clinical data in primary breast cancer
M. Sugimoto (2013)
Breast Conservation Therapy and Mastectomy
S. Mclaughlin (2013)
Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer
J. Vila (2017)
Prognostic significance of nuclear factor of activated T-cells 5 expression in non-small cell lung cancer patients who underwent surgical resection.
H. Cho (2018)
МАГНИТНО-РЕЗОНАНСНАЯ ТОМОГРАФИЯ В ОЦЕНКЕ ЭФФЕКТИВНОСТИ НЕОАДЪЮВАНТНОЙ ХИМИОТЕРАПИИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
А. В. Комяхов (2015)
The Impact of Neoadjuvant Chemotherapy on Local-Regional Treatment of Breast Cancer
E. P. Mamounas (2013)
The Role of Neoadjuvant Therapy in Melanoma
Z. Kelly (2020)
Neoadjuvant chemotherapy in breast cancers
S. Masood (2016)
Sentinel lymph node biopsy in breast cancer : aspects on indications and limitations
L. Zetterlund (2017)
Predictive Importance of Platelet to Lymphocyte Ratio and Neutrophil to Lymphocyte Ratio for Pathologic Complete Response in Locally Advanced Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
C. Geredeli (2018)
Targeted intraoperative radiotherapy tumour bed boost during breast-conserving surgery after neoadjuvant chemotherapy
H. Kolberg (2016)
Assessment of early response biomarkers in relation to long‐term survival in patients with HER2‐negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial
S. Kimbung (2018)
Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies
T. G. Steenbruggen (2017)
Assessment and Localisation of Response to Primary Systemic Therapy in Breast Cancer
F. Noble (2009)
Disseminated tumor cells predict survival after neoadjuvant therapy in primary breast cancer
C. Hall (2012)
Neoadjuvant radiotherapy in the approach of locally advanced breast cancer
C. Sousa (2020)
The role of surgery in metastatic breast cancer.
J. Ruiterkamp (2011)
Evaluation of Discordance in Primary Tumor and Lymph Node Response After Neoadjuvant Therapy in Breast Cancer
C. Fleming (2018)
Surrogate marker analysis in cancer clinical trials through time-to-event mediation techniques
S. Vandenberghe (2018)
Assessing the Clinical Benefit of Systemic Adjuvant Therapies for Early Breast Cancer
V. Moebus (2017)
The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer
A. Castrellon (2017)
Oncoplastic Breast Surgery Techniques for the General Surgeon
V. Klimberg (2020)See more